Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $351.6 million.

  • United Therapeutics' Free Cash Flow rose 1692.72% to $351.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2491.93%. This contributed to the annual value of $1.1 billion for FY2024, which is 4454.25% up from last year.
  • United Therapeutics' Free Cash Flow amounted to $351.6 million in Q3 2025, which was up 1692.72% from $129.5 million recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Free Cash Flow peaked at $386.3 million during Q1 2025, and registered a low of $61.6 million during Q2 2023.
  • Over the past 5 years, United Therapeutics' median Free Cash Flow value was $187.1 million (recorded in 2024), while the average stood at $201.9 million.
  • Per our database at Business Quant, United Therapeutics' Free Cash Flow crashed by 6071.43% in 2021 and then soared by 25347.22% in 2024.
  • United Therapeutics' Free Cash Flow (Quarter) stood at $104.0 million in 2021, then fell by 14.71% to $88.7 million in 2022, then dropped by 18.83% to $72.0 million in 2023, then surged by 253.47% to $254.5 million in 2024, then soared by 38.15% to $351.6 million in 2025.
  • Its Free Cash Flow stands at $351.6 million for Q3 2025, versus $129.5 million for Q2 2025 and $386.3 million for Q1 2025.